GlassScriptPhysician profile
Safrin Ali
NPI 1083084503
$2,237.24
in general payments reported to CMS, 2019-2025
27 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $840 · 2023: $357 · 2024: $383 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $356.83 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbott Laboratories | $303.12 | 2021-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $152.33 | 2022-2025 | Korlym |
| Lilly USA, LLC | $148.85 | 2022-2025 | Zepbound, Mounjaro |
| Tandem Diabetes Care, INC. | $83.71 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $75.83 | 2022-2024 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $70.39 | 2025 | Twiist |
| Abbvie INC. | $58.75 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $58.05 | 2022 | |
| Radius Health, INC. | $50.20 | 2022-2023 | Tymlos |
| Amphastar Pharmaceuticals, INC. | $49.92 | 2023-2024 | Baqsimi |
| Tolmar, INC. | $40.17 | 2023-2025 | Jatenzo |
| Insulet Corporation | $36.28 | 2022-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $33.68 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $30.17 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $27.67 | 2023-2025 | Qutenza |
| Sanofi-Aventis U.S. LLC | $26.19 | 2021 | |
| Antares Pharma, INC. | $25.03 | 2024 | Xyosted |
| Zealand Pharma US, INC. | $23.33 | 2021 | |
| Beta Bionics, INC. | $22.50 | 2024 | Ilet Bionic Pancreas |
| Bigfoot Biomedical INC | $19.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.72 | 2025 | Unithroid |
| Merck Sharp & Dohme LLC | $18.26 | 2023 | Steglujan, Steglatro |
| Astellas Pharma US INC | $13.60 | 2025 | Veozah |
| Ibsa Pharma INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safrin Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.